# A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

> **NCT04437433** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 186 (actual)

## Conditions studied

- Chronic Migraine
- Episodic Migraine

## Interventions

- **DRUG:** Atogepant 60 mg

## Key facts

- **NCT ID:** NCT04437433
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437433, "A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04437433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*